article Open AccessTop 1% cited

Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China

The Lancet Oncology · 2020 · Vol. 21(3) · pp. 335–337

Wenhua Liang✉(State Key Laboratory of Respiratory Disease)Wei‐jie Guan(State Key Laboratory of Respiratory Disease)Ruchong Chen(Guangzhou Medical University)Wei Wang(Guangzhou Medical University)Jianfu Li(First Affiliated Hospital of Guangzhou Medical University)Ke Xu(State Key Laboratory of Respiratory Disease)Caichen Li(Guangzhou Medical University)Qing Ai(State Key Laboratory of Respiratory Disease)Weixiang Lu(First Affiliated Hospital of Guangzhou Medical University)Hengrui Liang(Guangzhou Medical University)Shiyue Li(State Key Laboratory of Respiratory Disease)Jianxing He(State Key Laboratory of Respiratory Disease)

View via DOI Full-text PDF

COVID-19 Clinical Research Studies COVID-19 and healthcare impacts SARS-CoV-2 and COVID-19 ResearchOutbreakCoronavirusMedicineBetacoronavirusEpidemiologyPneumoniaPublic healthAtypical pneumoniaChinaMiddle East respiratory syndrome

MeSH terms

Age FactorsAgedAged, 80 and overBetacoronavirusCOVID-19SARS-CoV-2ChinaHumansMedical History TakingMiddle AgedNeoplasmsPneumonia, ViralPrognosisProspective StudiesRespiration, Artificial

Citations

4,570

FWCI

109.49

field-weighted impact

References

Percentile

100%

vs. same field & year

Citations per year

Cited by

Increased risk of pulmonary malignancy after second and on ward COVID attack with pleural effusion in South-West zone of Bangladesh